GalenOps prod · 0.1.0

Patients

1

Active

0

enrolled or consented

Withdrawn

0

Serious AEs

2

Open QA findings

0

Aged data queries

0

Studies & contracts

total budget 54500.00 USD

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Phase II study completed contract executed 54500 USD

Patients first 1

RefStatusConsentedStudy
P2B-035 completed 2012-09-11 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Luna participants 0

No Luna participants yet

Participants at this site have not been invited to Luna.

Safety

6 AEs · 2 serious

serious P2B-035 assessed

Grade 2 mucosal inflammation with onset in cycle 5 (2012-12-27); serious (hospitalization); assessed as related to study drug (probable); resolved 2013-01-05.

serious P2B-035 assessed

Grade 3 febrile neutropenia with onset in cycle 1 (2012-10-07); serious (hospitalization); assessed as related to study drug (probable); resolved 2012-10-13.

QA findings

0 open

No findings recorded

Findings are filed by monitoring visits.

Monitoring visits 0

No visits recorded

Re-score risk to propose an on-site visit.

Payments 0

No payments on file

Milestone payments are proposed by the finance step and approved in the review queue.